Pfizer Inc.

NYSE:PFE

Drug Manufacturers - General

Healthcare
$28.06 -2.72%

-$0.71 today

Market cap
$159.94B
Beta
0.29
P/E (TTM)
19.2
EPS (TTM)
$1.32
Dividend yield
6.82%
52W Low $23.11High $28.75

Volume 37.37M

Average 36.66M

PFE Debt Repayment

Cash used to repay borrowings during the period.

Pfizer Inc.NYSE: PFE

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment grows, but more slowly than its trailing trend

Q2 FY2026 debt repayment of $1.19B (cash outflow) rose 62.2% year over year, behind the +121.9% change in trailing-twelve-month debt repayment. Sequentially, it rose 833.9% from the prior quarter. Over 3 fiscal years it compounded at -72.4% a year.

Context

  • Debt repayment amounted to 0.1% of revenue in FY2025, down 11.1 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +62.2% toward the trailing-twelve-month pace of +121.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.19B+833.9% QoQ
Last fiscal yearDec 2025
-$74M-99.0% YoY
LTMJun 2026
$1.78B+121.9% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+62.2%——
1 year-99.0%——
3-year CAGR-72.4%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(74M) USD
Year-over-year change
+99.0%

Debt Repayment vs competitors

How PFE compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +121.9% is the 5th highest of 10, against a peer median of +98.1%.
  • Debt repayment amounts to 2.8% of revenue for PFE, versus a peer median of 5.4%.
PFE Competitors
Debt Repayment for PFE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$18.64B USD+723.0%—28.1%
NVSNovartis AGLTM Jun 2026$16.59B USD+704.5%—29.8%
LLYEli Lilly and CompanyLTM Jun 2026$15.22B USD+47.0%—19.1%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$6.49B USD+98.1%-0.9%13.2%
SNYSanofiLTM Jun 2026€3.21B EUR——6.6%
PFEPfizer Inc.LTM Jun 2026$1.78B USD+121.9%-72.4%2.8%
GILDGilead Sciences, Inc.LTM Jun 2026$1.29B USD-18.4%+6.0%4.2%
GSKGSK plcLTM Jun 2026£998.88M GBP+753.7%—3.0%
AZNAstraZeneca PLCLTM Sep 2026$793.27M USD+8.5%+11.3%1.3%
JNJJohnson & JohnsonLTM Sep 2026$787M USD-108.7%+8.9%0.8%
ABBVAbbVie Inc.LTM Jun 2026$418M USD+130.0%-70.3%0.6%
Peer median (excluding PFE) —+98.1%+6.0%5.4%

Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income22.46B31.4B2.17B8.05B7.79B
Depreciation & Amortization5.19B5.06B6.29B7.01B6.59B
Deferred Income Tax(4.29B)(3.76B)(3.44B)(2.1B)(2.13B)
Stock-Based Compensation1.18B872M525M877M799M
Change in Working Capital12.8B(4.46B)(2.17B)(3.07B)(5.35B)
Accounts Receivables(3.81B)261M347M(109M)(263M)
Inventory(1.13B)592M(1.17B)(854M)561M
Accounts Payables1.24B1.19B(300M)(1.02B)(469M)
Other Working Capital16.5B(6.5B)(1.05B)(1.08B)(5.18B)
Other Non-Cash Items(4.76B)150M5.33B1.97B4.01B
Operating Cash Flow32.58B29.27B8.7B12.74B11.71B
Capital Expenditures(2.71B)(3.24B)(3.91B)(2.91B)(2.63B)
Acquisitions (Net)(12M)(23B)(43.43B)7.04B(6.93B)
Purchases of Investments(47.61B)(38.78B)(31.18B)(10.31B)(14.65B)
Sales of Investments28.1B45.46B46.42B8.83B22.69B
Other Investing Activities(306M)3.77B(180M)0165M
Investing Cash Flow(22.55B)(15.78B)(32.28B)2.65B(1.35B)
Debt Repayment(1.1B)(3.52B)35.95B(7.16B)(74M)
Common Stock Issued00000
Common Stock Repurchased0(2B)000
Dividends Paid(8.73B)(8.98B)(9.25B)(9.51B)(9.77B)
Other Financing Activities16M(335M)(632M)(469M)(459M)
Financing Cash Flow(9.82B)(14.83B)26.07B(17.14B)(10.3B)
Effect of Forex Changes(60M)(165M)(40M)(66M)49M
Net Change in Cash158M(1.52B)2.45B(1.81B)99M
Free Cash Flow29.87B26.03B4.79B9.84B9.08B

Pfizer Inc.

NYSE:PFE

Intrinsic Alpha fair value

Locked

Current Price

$28.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.